Nephron Pharmaceuticals Corp. is investing $215.8 million in an expansion of its Lexington County operations expected to create 380 jobs.
West Columbia-based Nephron develops and produces generic inhalation solutions and suspension products, including those used to treat respiratory distress symptoms associated with COVID-19. It also produces pre-filled sterile syringes and IV bags for U.S. hospitals.
“The Nephron family is extraordinarily grateful for the opportunity to grow in South Carolina,” Nephron owner and CEO Lou Kennedy said in a news release. “Thanks to our partnerships with state and local officials, and the trust they have placed in us, we have been able to provide life-saving medications to patients around the world and establish ourselves as the global leader in what we do. We are proud of these achievements and more, and we know our best days are ahead of us.”
The expansion, expected to be completed by the first quarter of 2021, will add new offices, a warehouse, and vaccine production spaces at Nephron’s campus in Saxe-Gotha Industrial Park.
“We are excited to continue to partner with such an innovative and forward-thinking company like Nephron Pharmaceuticals,” Lexington County Council Chairman Scott Whetstone said. “We know that Lexington County is a great place to establish and grow a business, and Nephron’s continued success is a testament to good government-business relations.”
Nephron invested $313 million to move its headquarters from Florida to West Columbia in 2016. The company said more than 1,800 full- and part-time jobs have been created since that move.